{"success":true,"data":{"pressRelease":{"id":"142534","rtpr_id":"nPn9YRzpfa-20260914","ticker":"VNRX","exchange":"NYSE American","all_tickers":["VNRX"],"title":"VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027","author":"PR Newswire","published_at":"2026-09-14T12:17:00.082Z","article_body":"VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027\nPR Newswire\n\nHENDERSON, Nev., Sept. 14, 2026\n\nReduces Equity Overhang\n\nHENDERSON, Nev., Sept. 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE\nAMERICAN: VNRX) (\"Volition\"), a multi-national epigenetics company, today\nannounces the full pre-payment in cash of the outstanding balance on its\nsenior secured convertible promissory note, dated May 20, 2025, in the\noriginal principal amount of $7,500,000 (the \"Note\"), issued to Lind Global\nAsset Management XII LLC (\"Lind\"). Following the pre-payment, all obligations\nunder the Note have been satisfied. The senior secured convertible promissory\nnote, dated January 7, 2026, in the original principal amount of $2,400,000,\nalso issued to Lind, remains outstanding in the amount of $2,041,667.\n\nCameron Reynolds, Chief Executive Officer, Volition, commented:\n\n\"We are very pleased to be in a position to retire the outstanding balance of\nthis note to Lind, more than eight months ahead of our originally scheduled\nmaturity date.\n\n\"By prepaying the balance in cash, we prevent further potential dilution to\nour stockholders associated with the note.\n\n\"We are continuing to execute against our plan to improve Volition's financial\nposition and further debt and expense reduction remains a top priority moving\nforward as we seek to maximize stockholder value.\"\n\nAbout Volition\n\nVolition is a multi-national company focused on advancing the science of\nepigenetics. Volition is dedicated to saving lives and improving outcomes for\npeople and animals with life-altering diseases through earlier detection, as\nwell as disease and treatment monitoring.\n\nThrough its subsidiaries, Volition is developing and commercializing simple,\neasy to use, cost-effective blood tests to help detect and monitor a range of\ndiseases, including some cancers and diseases associated with NETosis, such as\nsepsis. Early detection and monitoring have the potential not only to prolong\nthe life of patients, but also to improve their quality of life.\n\nThe contents found at Volition's website address are not incorporated by\nreference into this document and should not be considered part of this\ndocument. Such website address is included in this document as an inactive\ntextual reference only.\n\nMedia Enquiries: Louise Batchelor, Volition, mediarelations@volition.com\n(mailto:mediarelations@volition.com) , +44 (0)7557 774620\n\nSafe Harbor Statement\n\nStatements in this press release may be \"forward-looking statements\" within\nthe meaning of Section 27A of the Securities Act of 1933, as amended, and\nSection 21E of the Securities Exchange Act of 1934, as amended, that concern\nmatters that involve risks and uncertainties that could cause actual results\nto differ materially from those anticipated or projected in the\nforward-looking statements. Words such as \"expects,\" \"anticipates,\" \"intends,\"\n\"plans,\" \"aims,\" \"targets,\" \"believes,\" \"seeks,\" \"estimates,\" \"optimizing,\"\n\"potential,\" \"goal,\" \"suggests,\" \"could,\" \"would,\" \"should,\" \"may,\" \"will\" and\nsimilar expressions identify forward-looking statements. These forward-looking\nstatements reflect the current belief and expectations of management and\nrelate to, among other topics, statements regarding the pre-payment of the\nNote and future reductions of debt and expenses. All statements other than\nstatements of historical fact are statements that could be deemed\nforward-looking statements. Although Volition believes that the expectations\nreflected in such forward-looking statements are reasonable, it can give no\nassurance that such expectations will prove to be correct. Forward-looking\nstatements are subject to risks and uncertainties that may cause Volition's\nactual activities or results to differ materially from those indicated or\nimplied by any forward- looking statement, including, without limitation, due\nto risks and uncertainties related to risks disclosed in the documents\nVolition files from time to time with the SEC, including Volition's Quarterly\nReports on Form 10-Q and Annual Reports on Form 10-K. These statements are\nbased on current expectations, estimates and projections about Volition's\nbusiness based, in part, on assumptions made by management. These statements\nare not guarantees of future performance and involve risks, uncertainties and\nassumptions that are difficult to predict. Forward-looking statements are made\nas of the date of this release, and, except as required by law, Volition does\nnot undertake an obligation to update its forward-looking statements to\nreflect future events or circumstances.\n\n \n\nView original\ncontent:https://www.prnewswire.com/news-releases/volitionrx-limited-announces-pre-payment-in-full-of-7-5-million-senior-secured-convertible-promissory-note-due-may-20--2027--302877586.html\n(https://www.prnewswire.com/news-releases/volitionrx-limited-announces-pre-payment-in-full-of-7-5-million-senior-secured-convertible-promissory-note-due-may-20--2027--302877586.html)\n\nSOURCE VolitionRx Limited\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn9YRzpfa-20260914","title":"VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027","author":"PR Newswire","ticker":"VNRX","created":"2026-09-14T12:17:00.082Z","tickers":["VNRX"],"exchange":"NYSE American","article_body":"VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027\nPR Newswire\n\nHENDERSON, Nev., Sept. 14, 2026\n\nReduces Equity Overhang\n\nHENDERSON, Nev., Sept. 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE\nAMERICAN: VNRX) (\"Volition\"), a multi-national epigenetics company, today\nannounces the full pre-payment in cash of the outstanding balance on its\nsenior secured convertible promissory note, dated May 20, 2025, in the\noriginal principal amount of $7,500,000 (the \"Note\"), issued to Lind Global\nAsset Management XII LLC (\"Lind\"). Following the pre-payment, all obligations\nunder the Note have been satisfied. The senior secured convertible promissory\nnote, dated January 7, 2026, in the original principal amount of $2,400,000,\nalso issued to Lind, remains outstanding in the amount of $2,041,667.\n\nCameron Reynolds, Chief Executive Officer, Volition, commented:\n\n\"We are very pleased to be in a position to retire the outstanding balance of\nthis note to Lind, more than eight months ahead of our originally scheduled\nmaturity date.\n\n\"By prepaying the balance in cash, we prevent further potential dilution to\nour stockholders associated with the note.\n\n\"We are continuing to execute against our plan to improve Volition's financial\nposition and further debt and expense reduction remains a top priority moving\nforward as we seek to maximize stockholder value.\"\n\nAbout Volition\n\nVolition is a multi-national company focused on advancing the science of\nepigenetics. Volition is dedicated to saving lives and improving outcomes for\npeople and animals with life-altering diseases through earlier detection, as\nwell as disease and treatment monitoring.\n\nThrough its subsidiaries, Volition is developing and commercializing simple,\neasy to use, cost-effective blood tests to help detect and monitor a range of\ndiseases, including some cancers and diseases associated with NETosis, such as\nsepsis. Early detection and monitoring have the potential not only to prolong\nthe life of patients, but also to improve their quality of life.\n\nThe contents found at Volition's website address are not incorporated by\nreference into this document and should not be considered part of this\ndocument. Such website address is included in this document as an inactive\ntextual reference only.\n\nMedia Enquiries: Louise Batchelor, Volition, mediarelations@volition.com\n(mailto:mediarelations@volition.com) , +44 (0)7557 774620\n\nSafe Harbor Statement\n\nStatements in this press release may be \"forward-looking statements\" within\nthe meaning of Section 27A of the Securities Act of 1933, as amended, and\nSection 21E of the Securities Exchange Act of 1934, as amended, that concern\nmatters that involve risks and uncertainties that could cause actual results\nto differ materially from those anticipated or projected in the\nforward-looking statements. Words such as \"expects,\" \"anticipates,\" \"intends,\"\n\"plans,\" \"aims,\" \"targets,\" \"believes,\" \"seeks,\" \"estimates,\" \"optimizing,\"\n\"potential,\" \"goal,\" \"suggests,\" \"could,\" \"would,\" \"should,\" \"may,\" \"will\" and\nsimilar expressions identify forward-looking statements. These forward-looking\nstatements reflect the current belief and expectations of management and\nrelate to, among other topics, statements regarding the pre-payment of the\nNote and future reductions of debt and expenses. All statements other than\nstatements of historical fact are statements that could be deemed\nforward-looking statements. Although Volition believes that the expectations\nreflected in such forward-looking statements are reasonable, it can give no\nassurance that such expectations will prove to be correct. Forward-looking\nstatements are subject to risks and uncertainties that may cause Volition's\nactual activities or results to differ materially from those indicated or\nimplied by any forward- looking statement, including, without limitation, due\nto risks and uncertainties related to risks disclosed in the documents\nVolition files from time to time with the SEC, including Volition's Quarterly\nReports on Form 10-Q and Annual Reports on Form 10-K. These statements are\nbased on current expectations, estimates and projections about Volition's\nbusiness based, in part, on assumptions made by management. These statements\nare not guarantees of future performance and involve risks, uncertainties and\nassumptions that are difficult to predict. Forward-looking statements are made\nas of the date of this release, and, except as required by law, Volition does\nnot undertake an obligation to update its forward-looking statements to\nreflect future events or circumstances.\n\n \n\nView original\ncontent:https://www.prnewswire.com/news-releases/volitionrx-limited-announces-pre-payment-in-full-of-7-5-million-senior-secured-convertible-promissory-note-due-may-20--2027--302877586.html\n(https://www.prnewswire.com/news-releases/volitionrx-limited-announces-pre-payment-in-full-of-7-5-million-senior-secured-convertible-promissory-note-due-may-20--2027--302877586.html)\n\nSOURCE VolitionRx Limited\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-14T12:17:00.139290534Z","server_sent_at_ms":1789388220139},"received_at":"2026-09-14T12:17:00.194Z","source_url":"https://www.prnewswire.com/news-releases/volitionrx-limited-announces-pre-payment-in-full-of-7-5-million-senior-secured-convertible-promissory-note-due-may-20--2027--302877586.html"},"analysis":{"id":"131367","press_release_id":"142534","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["second Lind convertible note remains outstanding ($2.04M), so residual conversion overhang persists","cash used for early prepayment reduces liquidity at a clinical-stage diagnostics company"],"eventType":"debt_offering","narrative":"VolitionRx announced the full cash pre-payment of the outstanding balance on its $7.5 million senior secured convertible promissory note issued to Lind Global Asset Management XII LLC, more than eight months ahead of its May 20, 2027 maturity date.\n\nCEO Cameron Reynolds said prepaying the balance in cash prevents further potential dilution to stockholders associated with the note, and that further debt and expense reduction remains a top priority.\n\nA second convertible note issued to Lind in January 2026, originally $2.4 million in principal, remains outstanding at $2,041,667.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Early cash retirement of $7.5M convertible note removes a dilution overhang on micro-cap VNRX, though a smaller Lind note still hangs over the stock."},"keyFigures":{"customDimensions":{"prepaid_note_maturity":"May 20, 2027","prepaid_note_principal":7500000,"remaining_note_balance":2041667,"early_payment_lead_time":"more than eight months ahead of scheduled maturity","second_note_original_principal":2400000}},"quotedText":"By prepaying the balance in cash, we prevent further potential dilution to","namedEntities":{"people":[{"name":"Cameron Reynolds","role":"Chief Executive Officer"},{"name":"Louise Batchelor","role":"media relations contact, Volition"}],"products":[],"companies":[{"name":"VolitionRx Limited","ticker":"VNRX","relationship":"filer / issuer"},{"name":"Lind Global Asset Management XII LLC","relationship":"noteholder / lender"}],"dollarAmounts":[{"amount":"$7,500,000","context":"original principal of senior secured convertible promissory note prepaid in full"},{"amount":"$2,400,000","context":"original principal of second Lind note dated January 7, 2026"},{"amount":"$2,041,667","context":"remaining outstanding balance of the January 2026 Lind note"}]},"materialImpact":{"score":3,"reasoning":"Volition retired its $7.5 million convertible note to Lind more than eight months early in cash, eliminating a conversion-based equity overhang on a micro-cap biotech. Meaningful for a company this size, but not a market-moving event; a second, smaller Lind note remains outstanding."},"tickerRelevance":{"others":[],"primary":"VNRX"},"globalImportance":20,"audienceRelevance":20,"eventTypeSecondary":["dilution"],"importanceComponents":{"dealSize":"$7.5M prepayment plus $2.04M note remaining","tickerTier":"micro-cap","eventGravity":"debt retirement and dilution-overhang reduction","sectorWeight":"biotech/diagnostics","issuerAuthored":true}},"event_type":"debt_offering","event_type_secondary":["dilution"],"sentiment":"bullish","material_impact_score":3,"narrative":"VolitionRx announced the full cash pre-payment of the outstanding balance on its $7.5 million senior secured convertible promissory note issued to Lind Global Asset Management XII LLC, more than eight months ahead of its May 20, 2027 maturity date.\n\nCEO Cameron Reynolds said prepaying the balance in cash prevents further potential dilution to stockholders associated with the note, and that further debt and expense reduction remains a top priority.\n\nA second convertible note issued to Lind in January 2026, originally $2.4 million in principal, remains outstanding at $2,041,667.","key_figures":{"customDimensions":{"prepaid_note_maturity":"May 20, 2027","prepaid_note_principal":7500000,"remaining_note_balance":2041667,"early_payment_lead_time":"more than eight months ahead of scheduled maturity","second_note_original_principal":2400000}},"named_entities":{"people":[{"name":"Cameron Reynolds","role":"Chief Executive Officer"},{"name":"Louise Batchelor","role":"media relations contact, Volition"}],"products":[],"companies":[{"name":"VolitionRx Limited","ticker":"VNRX","relationship":"filer / issuer"},{"name":"Lind Global Asset Management XII LLC","relationship":"noteholder / lender"}],"dollarAmounts":[{"amount":"$7,500,000","context":"original principal of senior secured convertible promissory note prepaid in full"},{"amount":"$2,400,000","context":"original principal of second Lind note dated January 7, 2026"},{"amount":"$2,041,667","context":"remaining outstanding balance of the January 2026 Lind note"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-14T12:17:22.459Z","global_importance":20,"audience_relevance":20,"importance_components":{"dealSize":"$7.5M prepayment plus $2.04M note remaining","tickerTier":"micro-cap","eventGravity":"debt retirement and dilution-overhang reduction","sectorWeight":"biotech/diagnostics","issuerAuthored":true}},"durationMs":22255,"modelName":"glm-5.3-flash"}}